{"hands_on_practices": [{"introduction": "Effective screening in a low-prevalence disease like ovarian cancer presents a significant statistical challenge. The clinical utility of a screening test hinges not only on its ability to detect disease (sensitivity) but, crucially, on its ability to correctly identify healthy individuals (specificity) to avoid an excess of false-positive results. This exercise demonstrates from first principles how to calculate the minimum specificity required for a screening test to achieve a clinically acceptable Positive Predictive Value (PPV), a fundamental skill in evaluating and implementing new diagnostic technologies. [@problem_id:4480526]", "problem": "A public health authority is evaluating a noninvasive screening test for epithelial ovarian cancer in an average-risk population. Assume the population prevalence of ovarian cancer is $1/2000$ and the test sensitivity is $0.80$. To minimize harm from unnecessary surgical interventions, the authority requires that the Positive Predictive Value (PPV) be at least $0.10$ before recommending diagnostic laparoscopy.\n\nStarting from first principles, use Bayesâ€™ theorem together with the core definitions of sensitivity, specificity, prevalence, and PPV to derive an analytic expression for the specificity required to achieve a PPV of $0.10$ at prevalence $1/2000$ and sensitivity $0.80$, and then compute its numerical value. Express the final specificity as a decimal fraction. Round your answer to four significant figures.", "solution": "The problem requires the derivation of an analytic expression for the required specificity of a screening test, followed by its numerical calculation. The derivation will be based on first principles, namely the definitions of prevalence, sensitivity, specificity, positive predictive value (PPV), and their relationship as described by Bayes' theorem.\n\nLet $D$ be the event that an individual has the disease (ovarian cancer), and $D^c$ be the event of not having the disease. Let $T$ be the event of a positive test result, and $T^c$ be the event of a negative test result.\n\nThe given quantities can be expressed in probabilistic terms as follows:\n-   Population prevalence, $Pr$: $P(D) = \\frac{1}{2000} = 0.0005$. Consequently, the probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - \\frac{1}{2000} = \\frac{1999}{2000} = 0.9995$.\n-   Test sensitivity, $Sens$: The probability of a positive test given disease, $P(T|D) = 0.80$.\n-   Required Positive Predictive Value, $PPV$: The probability of disease given a positive test, $P(D|T) = 0.10$.\n\nThe quantity to be determined is the test specificity, $Spec$, which is the probability of a negative test given the absence of disease: $Spec = P(T^c|D^c)$.\n\nWe will use the odds form of Bayes' theorem, a direct consequence of the fundamental theorem. This form relates the prior odds of disease to the posterior odds of disease via the likelihood ratio.\n\nThe prior odds of disease are the ratio of the probability of having the disease to the probability of not having it, before the test result is known:\n$$ \\text{Prior Odds} = \\frac{P(D)}{P(D^c)} = \\frac{Pr}{1 - Pr} $$\nSubstituting the given prevalence:\n$$ \\text{Prior Odds} = \\frac{1/2000}{1999/2000} = \\frac{1}{1999} $$\n\nThe posterior odds of disease are the same ratio, but updated with the evidence from a positive test result:\n$$ \\text{Posterior Odds} = \\frac{P(D|T)}{P(D^c|T)} = \\frac{P(D|T)}{1 - P(D|T)} = \\frac{PPV}{1 - PPV} $$\nSubstituting the required $PPV$:\n$$ \\text{Posterior Odds} = \\frac{0.10}{1 - 0.10} = \\frac{0.10}{0.90} = \\frac{1}{9} $$\n\nThe factor linking these two odds is the Likelihood Ratio of a positive test ($LR+$), defined as the ratio of the true positive rate to the false positive rate:\n$$ LR+ = \\frac{P(T|D)}{P(T|D^c)} $$\nThe numerator is the sensitivity ($Sens$). The denominator is the false positive rate, which equals $1$ minus the specificity ($1 - Spec$).\n$$ LR+ = \\frac{Sens}{1 - Spec} $$\n\nBayes' theorem in odds form is:\n$$ \\text{Posterior Odds} = LR+ \\times \\text{Prior Odds} $$\nSubstituting the expressions for each term yields:\n$$ \\frac{PPV}{1 - PPV} = \\left( \\frac{Sens}{1 - Spec} \\right) \\left( \\frac{Pr}{1 - Pr} \\right) $$\nTo find the analytic expression for specificity, we rearrange this equation to solve for $Spec$:\n$$ 1 - Spec = Sens \\cdot \\left( \\frac{Pr}{1 - Pr} \\right) \\cdot \\left( \\frac{1 - PPV}{PPV} \\right) $$\n$$ Spec = 1 - Sens \\cdot \\left( \\frac{Pr}{1 - Pr} \\right) \\left( \\frac{1 - PPV}{PPV} \\right) $$\nThis expression gives the required specificity as a function of prevalence, sensitivity, and the target positive predictive value.\n\nNow, we compute the numerical value. We have already calculated the odds ratios:\n-   $\\frac{Pr}{1 - Pr} = \\frac{1}{1999}$\n-   $\\frac{1 - PPV}{PPV} = 9$\n\nSubstituting these and the value for sensitivity ($Sens = 0.80$) into the expression for $1 - Spec$:\n$$ 1 - Spec = 0.80 \\cdot \\left( \\frac{1}{1999} \\right) \\cdot 9 $$\n$$ 1 - Spec = \\frac{0.80 \\times 9}{1999} = \\frac{7.2}{1999} $$\nThe value of this fraction is:\n$$ \\frac{7.2}{1999} \\approx 0.0036018009 $$\nFinally, we calculate the specificity:\n$$ Spec = 1 - \\frac{7.2}{1999} \\approx 1 - 0.0036018009 $$\n$$ Spec \\approx 0.9963981991 $$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $9$, $9$, $6$, and $3$. The fifth significant figure is $9$, so we round the fourth digit up.\n$$ Spec \\approx 0.9964 $$", "answer": "$$\\boxed{0.9964}$$", "id": "4480526"}, {"introduction": "While the goal of cancer screening is to improve mortality, an observed increase in survival time following the introduction of a screening program can be misleading. It is critical to distinguish true improvements in patient outcomes from statistical artifacts, such as lead-time bias, where earlier detection artificially inflates survival duration without altering the disease's natural history. This thought experiment isolates the effect of lead-time bias, providing a foundational understanding of how to critically appraise survival statistics reported in screening studies. [@problem_id:4480557]", "problem": "A cohort of patients with epithelial ovarian cancer is evaluated to understand the impact of screening on apparent survival. Without screening, the time from clinical detection to death, modeled as a non-increasing consequence of tumor burden, is treated as a random variable $T$ with survival function $S(t) = \\mathbb{P}(T \\ge t)$. Assume the following fundamental facts grounded in survival analysis: for a process with constant hazard $\\lambda$, the survival function is $S(t) = \\exp(-\\lambda t)$, and the median survival $m$ satisfies $S(m) = 0.5$. Suppose these patients have a median survival from clinical detection of $m = 3$ years, reflecting that half survive at least $3$ years after clinical detection. A screening program is introduced (e.g., using transvaginal ultrasonography and Cancer Antigen 125 (CA-125)) that advances the time of diagnosis uniformly by a lead-time $L = 2$ years, without changing the biological course or hazard of the disease; that is, survival measured from the moment of clinical detection remains distributed as $T$ and independent of $L$. Apparent survival is recorded from the moment of diagnosis, whether by screening or clinical detection, following standard oncologic reporting.\n\nGiven these assumptions, and acknowledging that historically reported $5$-year survival from clinical detection for this distribution is approximately $0.30$, derive from first principles the apparent $5$-year survival probability measured from the screening diagnosis that is attributable solely to the lead-time $L$ (with no change in hazard or treatment efficacy). Express your final answer as a decimal fraction, and do not use a percentage sign. No rounding is required.", "solution": "The setup uses standard survival analysis with constant hazard $\\lambda$ for time from clinical detection to death, represented by the random variable $T$ with survival function $S(t) = \\exp(-\\lambda t)$. The median survival $m$ is defined by the equation\n$$\nS(m) = \\mathbb{P}(T \\ge m) = 0.5.\n$$\nUnder the exponential survival model, this implies\n$$\n\\exp(-\\lambda m) = 0.5 \\quad \\Rightarrow \\quad \\lambda = \\frac{\\ln(2)}{m}.\n$$\nWith $m = 3$, the hazard becomes\n$$\n\\lambda = \\frac{\\ln(2)}{3}.\n$$\nThe historically reported $5$-year survival from clinical detection is given by\n$$\nS(5) = \\exp(-\\lambda \\cdot 5) = \\exp\\!\\left(-\\frac{5 \\ln(2)}{3}\\right) = 2^{-5/3},\n$$\nwhich is approximately $0.315$, close to $0.30$ as reported.\n\nNow incorporate the screening program that introduces a lead-time $L = 2$ years. Lead-time is defined as the amount by which the initial time of detection is advanced. If screening does not alter the biology or hazard of disease, then the actual time from clinical detectability to death remains $T$; however, the observed survival time from screening diagnosis is $T + L$, because the clock starts earlier by $L$ years.\n\nThe apparent $5$-year survival probability measured from the screening diagnosis is thus\n$$\n\\mathbb{P}(T + L \\ge 5) = \\mathbb{P}(T \\ge 5 - L) = S(5 - L).\n$$\nSubstituting $L = 2$ and using the exponential survival function with $\\lambda = \\ln(2)/3$,\n$$\nS(5 - 2) = S(3) = \\exp(-\\lambda \\cdot 3) = \\exp\\!\\left(-\\frac{\\ln(2)}{3} \\cdot 3\\right) = \\exp(-\\ln(2)) = \\frac{1}{2}.\n$$\nTherefore, the apparent $5$-year survival measured from screening diagnosis, attributable solely to a $2$-year lead-time gain with unchanged median survival of $3$ years, is exactly $0.5$. This illustrates lead-time bias: the $5$-year survival measured from diagnosis increases from $S(5) = 2^{-5/3} \\approx 0.315$ to $S(3) = 0.5$, even though there is no change in the underlying hazard or median survival from clinical detection.", "answer": "$$\\boxed{0.5}$$", "id": "4480557"}, {"introduction": "Translating evidence from clinical trials into personalized guidance is a core task in genetic counseling and preventative oncology, especially for high-risk individuals such as $BRCA$ mutation carriers. While studies often report the efficacy of an intervention like risk-reducing salpingo-oophorectomy (RRSO) in terms of relative risk reduction, patients benefit from understanding the absolute change in their personal risk. This practice problem provides the tools to convert relative risk metrics into Absolute Risk Reduction (ARR), a more intuitive value that quantifies the tangible benefit of a preventative strategy and facilitates shared decision-making. [@problem_id:4480586]", "problem": "A cancer genetics counselor is evaluating the effect of Risk-Reducing Salpingo-Oophorectomy (RRSO) on lifetime risk of epithelial ovarian, fallopian tube, and primary peritoneal carcinoma in carriers of Breast Cancer Gene 1 (BRCA1) and Breast Cancer Gene 2 (BRCA2). Let lifetime risk be the cumulative probability of developing the disease over the remaining lifespan. Suppose the following are well-supported starting points: (i) baseline lifetime risk for BRCA1 carriers is $0.40$ and for BRCA2 carriers is $0.20$; (ii) RRSO yields a relative risk reduction of $80\\%$ for both BRCA1 and BRCA2 carriers; (iii) absolute risk reduction is defined as the difference between the baseline risk and the post-intervention risk.\n\nStarting from the definition of relative risk reduction and the definition of absolute risk reduction, derive the post-intervention lifetime risk for each gene, and then compute the absolute risk reduction for BRCA1 and BRCA2 carriers. Express both absolute risk reductions as decimal fractions with no units, placed in a single row matrix in the order $\\text{BRCA1}$ then $\\text{BRCA2}$. Round your answers to three significant figures.", "solution": "The first step is to formalize the given information using mathematical notation. Let $R_{\\text{base}}$ denote the baseline lifetime risk and $R_{\\text{post}}$ denote the post-intervention lifetime risk. Let the subscripts $1$ and $2$ refer to carriers of Breast Cancer Gene 1 ($\\text{BRCA1}$) and Breast Cancer Gene 2 ($\\text{BRCA2}$), respectively.\n\nThe given data are:\nBaseline lifetime risk for $\\text{BRCA1}$ carriers: $R_{\\text{base,1}} = 0.40$\nBaseline lifetime risk for $\\text{BRCA2}$ carriers: $R_{\\text{base,2}} = 0.20$\nRelative risk reduction for both groups: $RRR = 80\\% = 0.80$\n\nThe problem requires a two-part calculation: first, finding the post-intervention lifetime risk for each group ($R_{\\text{post,1}}$ and $R_{\\text{post,2}}$), and second, computing the absolute risk reduction ($ARR_1$ and $ARR_2$) for each group.\n\nThe relative risk reduction ($RRR$) is defined as the proportional decrease in risk after an intervention. Mathematically, it is expressed as the difference between the baseline risk and the post-intervention risk, divided by the baseline risk:\n$$RRR = \\frac{R_{\\text{base}} - R_{\\text{post}}}{R_{\\text{base}}}$$\n\nTo find the post-intervention lifetime risk, we must rearrange this formula to solve for $R_{\\text{post}}$.\n$$RRR \\cdot R_{\\text{base}} = R_{\\text{base}} - R_{\\text{post}}$$\n$$R_{\\text{post}} = R_{\\text{base}} - (RRR \\cdot R_{\\text{base}})$$\nFactoring out $R_{\\text{base}}$, we get a general formula for post-intervention risk:\n$$R_{\\text{post}} = R_{\\text{base}}(1 - RRR)$$\n\nNow, we apply this formula to each carrier group.\nFor $\\text{BRCA1}$ carriers:\n$$R_{\\text{post,1}} = R_{\\text{base,1}}(1 - RRR) = 0.40(1 - 0.80) = 0.40(0.20) = 0.08$$\nThe post-intervention lifetime risk for a $\\text{BRCA1}$ carrier is $0.08$.\n\nFor $\\text{BRCA2}$ carriers:\n$$R_{\\text{post,2}} = R_{\\text{base,2}}(1 - RRR) = 0.20(1 - 0.80) = 0.20(0.20) = 0.04$$\nThe post-intervention lifetime risk for a $\\text{BRCA2}$ carrier is $0.04$.\n\nThe second part of the task is to compute the absolute risk reduction ($ARR$) for each group. The problem provides the definition: absolute risk reduction is the difference between the baseline risk and the post-intervention risk.\n$$ARR = R_{\\text{base}} - R_{\\text{post}}$$\n\nUsing the values we have calculated, we find the $ARR$ for each group.\nFor $\\text{BRCA1}$ carriers:\n$$ARR_1 = R_{\\text{base,1}} - R_{\\text{post,1}} = 0.40 - 0.08 = 0.32$$\n\nFor $\\text{BRCA2}$ carriers:\n$$ARR_2 = R_{\\text{base,2}} - R_{\\text{post,2}} = 0.20 - 0.04 = 0.16$$\n\nThe problem specifies that the final answers should be rounded to three significant figures.\nThe value for $ARR_1$ is $0.32$. To express this with three significant figures, we write $0.320$.\nThe value for $ARR_2$ is $0.16$. To express this with three significant figures, we write $0.160$.\n\nThe final answer should be presented as a single row matrix with the absolute risk reductions in the order of $\\text{BRCA1}$ then $\\text{BRCA2}$.\nThe resulting matrix is $\\begin{pmatrix} 0.320 & 0.160 \\end{pmatrix}$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.320 & 0.160\n\\end{pmatrix}\n}\n$$", "id": "4480586"}]}